Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study Astellas FSGS
View study details on ClinicalTrials.gov
Patients at least 18years old who has a biopsy-proven, pFSGS as a cause of ESRD in their native kidneys are eligible for the study. Patients who previously received an organ transplant and patients who will be receiving multi-organ or dual kidney transplants are not eligible for the study. Status: Active and open to enrollment.
June 01, 2018